2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
July 5, 2017
Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
June 20, 2017
Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
June 15, 2017
Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
June 12, 2017
Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
June 8, 2017
Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
June 7, 2017
Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
May 11, 2017
Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
May 9, 2017
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
May 8, 2017
Aimmune Therapeutics Announces First Quarter 2017 Financial Results
April 13, 2017
Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
March 15, 2017
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
March 8, 2017
Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
March 6, 2017
Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
March 1, 2017
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
February 27, 2017
Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 16, 2017
Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
January 4, 2017
Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference